The SGLT2 inhibitor empagliflozin (Jardiance) was approved by European regulators for treating adults with chronic kidney disease. The FDA is reviewing a new drug application for this indication.
Lilly (LLY) announces Jardiance approved in the EU for the treatment of adults with chronic kidney disease streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
The European Commission (EC) approved Jardiance® (empagliflozin) for the treatment of adults with chronic kidney disease (CKD)[viii], Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced today. The approval has the potential to advance the standard of care for more than 47 million people in the EU .
The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has granted a positive opinion recommending Jardiance empagliflozin for the treatment of adults with chronic kidney disease CKD Boehringer Ingelheim and Eli Lilly and Company NYSE LLY announced today.1
Boehringer Ingelheim: Jardiance recommended for the treatment of adults with chronic kidney disease in the EU finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.